Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management

Jafar Kafaie, MD, PhD


June 24, 2021

In PATH, a randomized, double-blind trial and the largest CIDP trial to date, the primary outcome measure was met: Subcutaneous immunoglobulin (SCIg) reduced the number of relapses or withdrawals more than placebo in patients with CIDP who responded to IVIg, an established treatment for CIDP. The takeaway from this landmark trial is that patients with CIDP who have stabilized with IVIg may switch to treatment with SCIg.

Learn more about treatment with immunomodulatory/immunosuppressive agents.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.